Stage III Prostate Cancer Clinical Trial
Official title:
Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
This randomized phase III trial studies how well decision aids work in improving knowledge in patients with newly diagnosed prostate cancer. Decision aids may improve patients' knowledge of their condition and options for treatment, and may also help when talking with their doctor.
PRIMARY OBJECTIVES: I. To test the comparative effectiveness of decision aids (DA's) on patient knowledge. SECONDARY OBJECTIVES: I. To test the impact of in-visit DA's alone compared to usual care on quality of life outcomes and treatment utilization. II. To test the impact of out-of-visit DA's alone compared to usual care on quality of life outcomes and treatment utilization. III. To test the impact of combined in-visit and out-of-visit DA's compared to both usual care and individual DAs on quality of life outcomes and treatment utilization. IV. To test the comparative effectiveness of DA's on minority men's knowledge. V. To compare clinic time required to administer the DA's across arms. OUTLINE: Patients are randomized into 1 of 4 arms. ARM A: Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit. ARM B: Patients receive "Knowing your Options" decision aid before their consultation visit. ARM C: Patients receive "Prostate Choice" decision aid during their consultation visit. ARM D: Patients undergo usual care. After completion of study, patients are followed up at 12 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT02846870 -
Visually Enhanced Education About Prostate Cancer
|
N/A | |
Completed |
NCT00103194 -
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT01385059 -
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
|
Phase 2 | |
Terminated |
NCT00536991 -
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04589468 -
Researching the Effect of Exercise on Cancer
|
N/A | |
Active, not recruiting |
NCT01823562 -
Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
|
Phase 1 | |
Active, not recruiting |
NCT01923506 -
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
|
Phase 1 | |
Recruiting |
NCT02605226 -
Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
|
N/A | |
Completed |
NCT00589472 -
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02278185 -
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
|
Phase 2 | |
Completed |
NCT01117935 -
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
|
N/A | |
Completed |
NCT01731912 -
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
|
N/A | |
Withdrawn |
NCT00996749 -
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer
|
N/A | |
Completed |
NCT01656304 -
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
Recruiting |
NCT03880422 -
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
|
N/A | |
Completed |
NCT02048150 -
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
|
Phase 1 | |
Withdrawn |
NCT01555632 -
Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
|
N/A | |
Completed |
NCT00956163 -
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
|
Phase 0 |